| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 17 | 2018 | 459 | 1.520 |
Why?
|
| Cancer Vaccines | 5 | 2020 | 156 | 1.320 |
Why?
|
| Immunotherapy, Adoptive | 9 | 2019 | 170 | 1.220 |
Why?
|
| Receptors, Antigen, T-Cell | 11 | 2022 | 372 | 1.030 |
Why?
|
| T-Lymphocytes | 9 | 2019 | 1195 | 1.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2014 | 138 | 0.970 |
Why?
|
| MART-1 Antigen | 4 | 2018 | 19 | 0.770 |
Why?
|
| Immunotherapy | 5 | 2020 | 629 | 0.760 |
Why?
|
| Ovarian Neoplasms | 3 | 2022 | 744 | 0.680 |
Why?
|
| Dendritic Cells | 4 | 2023 | 425 | 0.660 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2022 | 559 | 0.620 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 418 | 0.600 |
Why?
|
| Antibodies, Monoclonal | 5 | 2015 | 1376 | 0.550 |
Why?
|
| Indoles | 7 | 2014 | 318 | 0.550 |
Why?
|
| Immunotherapy, Active | 2 | 2015 | 15 | 0.540 |
Why?
|
| Sulfonamides | 6 | 2014 | 300 | 0.520 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 123 | 0.500 |
Why?
|
| Skin Neoplasms | 6 | 2018 | 546 | 0.500 |
Why?
|
| Antineoplastic Agents | 7 | 2016 | 2360 | 0.470 |
Why?
|
| Lymphocytes | 3 | 2014 | 464 | 0.460 |
Why?
|
| Antigens, Neoplasm | 4 | 2022 | 325 | 0.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 425 | 0.350 |
Why?
|
| Neoplasms | 4 | 2022 | 2898 | 0.290 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2018 | 315 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 592 | 0.270 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2019 | 272 | 0.260 |
Why?
|
| Keloid | 2 | 2003 | 8 | 0.260 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2023 | 112 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2014 | 222 | 0.240 |
Why?
|
| Carbonic Anhydrase IX | 2 | 2020 | 11 | 0.220 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 426 | 0.220 |
Why?
|
| Genetic Therapy | 3 | 2015 | 342 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2013 | 589 | 0.220 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2022 | 23 | 0.210 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 329 | 0.210 |
Why?
|
| Receptors, CXCR6 | 1 | 2021 | 5 | 0.210 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 17 | 0.210 |
Why?
|
| Kidney Neoplasms | 2 | 2020 | 621 | 0.200 |
Why?
|
| Fibroblasts | 2 | 2003 | 729 | 0.200 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 54 | 0.200 |
Why?
|
| Humans | 34 | 2023 | 86643 | 0.200 |
Why?
|
| Autocrine Communication | 1 | 2000 | 18 | 0.190 |
Why?
|
| Transduction, Genetic | 4 | 2014 | 153 | 0.190 |
Why?
|
| fas Receptor | 1 | 2000 | 75 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 307 | 0.180 |
Why?
|
| Antigens, CD | 3 | 2010 | 458 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 2 | 2003 | 301 | 0.180 |
Why?
|
| Apoptosis | 3 | 2014 | 1683 | 0.180 |
Why?
|
| Cells, Cultured | 6 | 2018 | 2818 | 0.170 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 2426 | 0.170 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2019 | 10 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2016 | 930 | 0.160 |
Why?
|
| CTLA-4 Antigen | 3 | 2014 | 135 | 0.160 |
Why?
|
| Lymphocyte Activation | 6 | 2022 | 728 | 0.150 |
Why?
|
| Female | 17 | 2022 | 44532 | 0.150 |
Why?
|
| Neoplasm Metastasis | 4 | 2014 | 1056 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 878 | 0.140 |
Why?
|
| Cell Survival | 3 | 2019 | 969 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 262 | 0.140 |
Why?
|
| Cell Cycle | 2 | 2015 | 502 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 322 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 329 | 0.130 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2014 | 3 | 0.130 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 94 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1686 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 85 | 0.120 |
Why?
|
| Peptide Fragments | 2 | 2014 | 460 | 0.120 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 39 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2010 | 532 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2014 | 3241 | 0.110 |
Why?
|
| Carbonic Anhydrases | 1 | 2013 | 15 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 292 | 0.110 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 250 | 0.110 |
Why?
|
| Vaccination | 1 | 2014 | 254 | 0.110 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1939 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2010 | 132 | 0.100 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 244 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2012 | 131 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2011 | 23 | 0.100 |
Why?
|
| Middle Aged | 10 | 2018 | 25028 | 0.100 |
Why?
|
| Animals | 8 | 2022 | 26582 | 0.100 |
Why?
|
| K562 Cells | 1 | 2010 | 43 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 64 | 0.100 |
Why?
|
| Antineoplastic Protocols | 1 | 2010 | 9 | 0.100 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 181 | 0.100 |
Why?
|
| Mice | 7 | 2022 | 11352 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2020 | 7993 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 104 | 0.100 |
Why?
|
| Antibodies, Blocking | 1 | 2010 | 21 | 0.100 |
Why?
|
| Genes, ras | 1 | 2010 | 96 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2015 | 395 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2010 | 1578 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 188 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 153 | 0.090 |
Why?
|
| Epitopes | 1 | 2010 | 255 | 0.090 |
Why?
|
| Male | 12 | 2018 | 40965 | 0.090 |
Why?
|
| Adult | 9 | 2018 | 25648 | 0.090 |
Why?
|
| Protein Engineering | 1 | 2010 | 140 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2014 | 196 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 1197 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1961 | 0.070 |
Why?
|
| Antibodies | 2 | 2013 | 350 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2010 | 692 | 0.060 |
Why?
|
| Aged | 7 | 2018 | 18415 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2018 | 211 | 0.060 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2003 | 87 | 0.060 |
Why?
|
| Caspases | 2 | 2002 | 155 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2601 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 189 | 0.060 |
Why?
|
| Gelsolin | 1 | 2002 | 11 | 0.060 |
Why?
|
| Keratinocytes | 1 | 2003 | 143 | 0.060 |
Why?
|
| Cell Communication | 1 | 2003 | 194 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2023 | 331 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2013 | 28 | 0.050 |
Why?
|
| NAD | 1 | 2022 | 65 | 0.050 |
Why?
|
| Granzymes | 1 | 2022 | 93 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2023 | 326 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 90 | 0.050 |
Why?
|
| Staurosporine | 1 | 2000 | 33 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2000 | 52 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2000 | 47 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2013 | 615 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2000 | 256 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2014 | 164 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 853 | 0.040 |
Why?
|
| Cytokines | 2 | 2014 | 776 | 0.040 |
Why?
|
| Phenotype | 2 | 2018 | 2378 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 327 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2018 | 69 | 0.040 |
Why?
|
| Mutation | 3 | 2014 | 3968 | 0.040 |
Why?
|
| Base Sequence | 2 | 2012 | 2330 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2018 | 152 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 645 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2232 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2021 | 1924 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 6509 | 0.040 |
Why?
|
| Cell Line | 2 | 2012 | 2468 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1981 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2010 | 712 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2002 | 1464 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 159 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2014 | 24 | 0.030 |
Why?
|
| Oximes | 1 | 2013 | 14 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 158 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 49 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2013 | 15 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 100 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 2438 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily A | 1 | 2013 | 3 | 0.030 |
Why?
|
| Chemokine CCL1 | 1 | 2013 | 4 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2013 | 56 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2013 | 177 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 128 | 0.030 |
Why?
|
| Proteome | 1 | 2014 | 124 | 0.030 |
Why?
|
| ras Proteins | 1 | 2013 | 128 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 162 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2014 | 439 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 85 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2013 | 164 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2013 | 146 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2014 | 254 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2014 | 134 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 163 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2012 | 36 | 0.030 |
Why?
|
| DNA Damage | 1 | 2014 | 366 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2012 | 103 | 0.030 |
Why?
|
| Microchip Analytical Procedures | 1 | 2011 | 3 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 115 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 286 | 0.030 |
Why?
|
| Exome | 1 | 2012 | 127 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 171 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2010 | 18 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 140 | 0.020 |
Why?
|
| Monophenol Monooxygenase | 1 | 2010 | 9 | 0.020 |
Why?
|
| Lentivirus | 1 | 2010 | 36 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 528 | 0.020 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2010 | 38 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 1047 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 1041 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 196 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 101 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 290 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 192 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 286 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2010 | 268 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2010 | 114 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2009 | 38 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2010 | 203 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 679 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 989 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2009 | 101 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 1284 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1540 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 689 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 376 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2009 | 160 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 534 | 0.020 |
Why?
|
| Macrophages | 1 | 2011 | 554 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1196 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 1513 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1351 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3092 | 0.020 |
Why?
|
| Paracrine Communication | 1 | 2003 | 31 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2003 | 104 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 113 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2002 | 34 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2002 | 48 | 0.010 |
Why?
|
| Mesentery | 1 | 2002 | 45 | 0.010 |
Why?
|
| Nevus, Pigmented | 1 | 2002 | 49 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 696 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 782 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2003 | 1106 | 0.010 |
Why?
|
| Skin | 1 | 2003 | 554 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 533 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 2062 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3030 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 1313 | 0.010 |
Why?
|
| Child | 1 | 2003 | 6927 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 8981 | 0.010 |
Why?
|